Next Article in Journal
Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma
Previous Article in Journal
UNCOVID—A 55-Word Story
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Immunotherapy in Soft-Tissue Sarcoma

Toronto Sarcoma Program, Princess Margaret Cancer Centre and Mount Sinai Hospital, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s1), 17-23; https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.5407
Received: 6 November 2019 / Revised: 12 December 2019 / Accepted: 10 January 2020 / Published: 1 February 2020
Soft-tissue sarcoma (sts) is a rare mesenchymal malignancy that accounts for less than 1% of all adult tumours. Despite the successful advancement of localized therapies such as surgery and radiotherapy, these tumours can, for many, recur—often with metastatic disease. In the advanced setting, the role of systemic therapies is modest and is associated with poor survival. With the discovery of immunotherapies in other tumour types such as melanoma and lung cancer, interest has been renewed in exploring immunotherapy in sts. The biology of some stss makes them ripe for immunotherapy intervention; for example, some stss might have chromosomal translocations resulting in pathognomonic fusion products that have been shown to express cancer/testis antigens. Here, we present a targeted review of the published data and ongoing clinical trials for immunotherapies in patients with sarcoma, which comprise immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines.
Keywords: adoptive cell therapy; cancer vaccines; immunotherapy; checkpoint inhibitors; soft-tissue sarcoma; alveolar soft-part sarcoma; undifferentiated pleomorphic sarcoma adoptive cell therapy; cancer vaccines; immunotherapy; checkpoint inhibitors; soft-tissue sarcoma; alveolar soft-part sarcoma; undifferentiated pleomorphic sarcoma
MDPI and ACS Style

Ayodele, O.; Razak, A.R.A. Immunotherapy in Soft-Tissue Sarcoma. Curr. Oncol. 2020, 27, 17-23. https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.5407

AMA Style

Ayodele O, Razak ARA. Immunotherapy in Soft-Tissue Sarcoma. Current Oncology. 2020; 27(s1):17-23. https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.5407

Chicago/Turabian Style

Ayodele, O., and A.R. Abdul Razak. 2020. "Immunotherapy in Soft-Tissue Sarcoma" Current Oncology 27, no. s1: 17-23. https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.5407

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop